Back to search results

Remotely-supervised Neuromodulation in PPA

This study is looking at whether combining home-based brain stimulation (called transcranial direct current stimulation or tDCS) with virtual speech therapy can help adults with logopenic variant primary progressive aphasia (lvPPA), a language problem often linked to Alzheimer's disease. You might be eligible if you are 40 or older, have been diagnosed with PPA or lvPPA, and meet certain cognitive and technical requirements. The researchers will measure improvements in your spoken naming ability one and three months after treatment. The study aims to enroll 80 participants, but its current recruitment status is unclear.

Study design
This interventional study plans to enroll 80 participants. It compares active tDCS with speech therapy to a sham (placebo) tDCS with speech therapy.
What's involved
Participants will receive tDCS stimulation 5 times weekly for 20 minutes in their home setting, while also working on a Lexical Retrieval Cascade Treatment.
Compensation
Not stated in the trial record.
Follow-up
Researchers will measure changes in spoken naming one month and three months after treatment begins.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07260253

Remotely-supervised Neuromodulation in PPA

Recruiting
NAAges 40+InterventionalTreatment
Maya Henry
~80 participants
Updated 2026-06-29 on ClinicalTrials.gov
What's tested:Lexical Retrieval Cascade TreatmentRemotely Supervised Transcranial Direct Current Stimulation- ActiveRemotely Supervised Transcranial Direct Current Stimulation - Sham

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in spoken naming
Measured over change from pre-treatment to one month and three months after onset of treatment in each phase (stimulation and sham)

Conditions

Primary Progressive Aphasia(PPA)
Progressive Aphasia
Progressive Aphasia in Alzheimer's Disease
Logopenic Progressive Aphasia (LPA)
Logopenic Variant Primary Progressive Aphasia
Logopenic Variant of Primary Progressive Aphasia (LPA)

Explore related trials

Logopenic Variant Primary Progressive Aphasia

Where it's being run

2 sites across 2 states
California1
Texas1

Study leadership

  • Maya L Henry, PhD · PRINCIPAL_INVESTIGATOR · University of Texas at Austin
  • Jessica D Richardson, PhD · PRINCIPAL_INVESTIGATOR · University of New Mexico

Who to contact

Aphasia Lab Research Coordinator
[email protected]
512-471-3420
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Meets diagnostic criteria for primary progressive aphasia (PPA)
Meets diagnostic criteria for logopenic variant PPA
Attains score of 15 or higher on the Mini-Mental State Examination
Has adequate hearing and vision (with hearing or vision aids, if needed)
Is able to travel to research site and undergo MRI brain scan
Has access to high speed internet and basic experience using a computer and the internet
Is a fluent speaker of English
Has a study partner who can co-enroll in the study, attend pre-treatment training at the research site, and be present for teleconference meetings, as needed

Exclusion

Speech and language deficits better accounted for by another neurological disorder
Does not meet diagnostic criteria for logopenic variant PPA
Scores less than 15 on the Mini-Mental State Examination
Does not have a study partner who can co-enroll in the study
Has contraindications for tDCS or MRI scan (History of seizures, head injury, craniotomy, skull surgery or fracture; History of severe or frequent migraines; Metallic implant in head or any metal in head; Pacemaker or cardioverter-defibrillator or any other stimulator; Chronic skin problems; Pregnancy)
Has a history of stroke, epilepsy, or significant brain injury

What this trial measures

  • Change in spoken namingchange from pre-treatment to one month and three months after onset of treatment in each phase (stimulation and sham)

    Change in percent correctly named trained/untrained pictures